Drug
Mas825
Mas825: highest development phase Phase 2, developed by Novartis. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Novartis
Trials
| Drug | Phase | Indication |
|---|---|---|
| MAS825 NCT07203001 | Phase 2 | Still´s Disease |
Latest
No recent events.
Follow Mas825 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.